Washington Business Journal on SBIR

Washington Business Journal
The House passed legislation that would make small businesses majority-owned by venture capital firms eligible for Small Business Innovation Research awards.
Through the SBIR program, 2.5 percent of the outside research budgets of 11 federal agencies — including the Department of Defense and the National Institutes of Health — is allocated for small [...]

National Dialogue on Entrepreneurship

The National Dialogue on Entrepreneurship is following the SBIR Debate:

SBIR Bill Advances
A new proposal to reauthorize and modernize the Small Business Innovation Research (SBIR) program is making fast progress through Congress. Late last month, the House of Representatives overwhelmingly passed H.R. 5819, a bill to reauthorize the SBIR program—which directs federal research funds [...]

Cystic Fibrosis Foundation Lauds Congress

The Cystic Fibrosis Foundation today lauded the U.S. House of Representatives for passing legislation to reauthorize the Small Business Innovation Research (SBIR) program.
 

 
In response to testimony from Robert J. Beall, Ph.D., president and CEO of the Foundation, the legislation includes a provision requiring that special attention be given to research for rare diseases, such as [...]

Conversation with the Cystic Fibrosis Foundation

 
The Cystic Fibrosis Foundation is the leading organization in the United States devoted to curing and controlling cystic fibrosis. We spoke with Mary Dwight about her organization and the important work they do.
 Can you tell us a bit about CFF’s purpose?  The Cystic Fibrosis Foundation is the leader in developing drugs to treat and [...]

House Small Business Committee Holds SBIR Hearing

House Small Business Committee Holds Hearing on the Reauthorization of the Small Business Innovation Research Program 
Witness List 
March 13, 2008 
Chairwoman Velazquez’s (NY-12) led a lively hearing on the SBIR program in helping small businesses support promising research. She emphasized the importance of reinstating eligibility of majority venture capital-backed companies and highlighted the remedy offered in the [...]

Putting the “I” Back into SBIR

Putting the “I” back — that is the “I” in innovation. While we consider SBIR program to be critical to the commercialization of biotechnology for our industry, it is clear that others do not share this view ordiffer on the ways in which this problem should be fixed. For example, Kristie Prinz wrote [...]